grant
Enhancing Dendritic Cell Migration to Draining Sentinel Nodes to Improve Immunotherapy Response in HPV negative HNSCC
Organization UNIVERSITY OF CALIFORNIA, SAN DIEGOLocation LA JOLLA, UNITED STATESPosted 20 Jun 2025Deadline 31 May 2030
NIHUS FederalResearch GrantFY20256-C-kine6-Ckine6CkineAbscissionActivities of Daily LivingActivities of everyday lifeAgonistAntigen PresentationAssayBioassayBiological AssayBp50CCL-21 chemokineCCL19CCL19 geneCD40CDW40CKb11Cancer CauseCancer EtiologyCancersCell BodyCell FunctionCell LocomotionCell MigrationCell MovementCell PhysiologyCell ProcessCellsCellular FunctionCellular MigrationCellular MotilityCellular PhysiologyCellular ProcessClinicalCross PresentationDendritic CellsDevelopmentExcisionExodus-2 chemokineExtirpationFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryGenerationsGoalsHNC patientHNSCCHPV [-]HPV negativeHPV(-)HPV(-) HNSCCHPV(-) head and neck squamous cell carcinomaHPV- HNSCCHPV-negative HNSCCHPV-negative head and neck cancerHPV-negative head and neck squamous cell carcinomaHead and Neck CancerHead and Neck CarcinomaHead and Neck Squamous Cell CarcinomaImmuneImmune mediated therapyImmune responseImmunesImmunochemical ImmunologicImmunologicImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunoradiotherapyImmunotherapyInduction TherapyLigandsLymphaticMGC34433MGC9013MIP-3bMIP3BMalignant Head and Neck NeoplasmMalignant NeoplasmsMalignant TumorMetastatic/RecurrentModelingMorbidityMorbidity - disease rateNEOADJNeoadjuvantNeoadjuvant TherapyNeoadjuvant TreatmentNodalOperative ProceduresOperative Surgical ProceduresPD 1PD-1PD-1 inhibitorsPD1PD1 inhibitorsPathologicPatientsPhase 2 Clinical TrialsPhase II Clinical TrialsPhenotypePrimary NeoplasmPrimary TumorRNA SeqRNA sequencingRNAseqRadiationRadioimmunotherapyRemovalReportingResearchRoleSCCHNSCYA19SLC proteinSecondary Lymphoid Tissue ChemokineSentinelSentinel Lymph NodeSentinel NodeSmall Inducible Cytokine A21Solid NeoplasmSolid TumorSubcellular ProcessSurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalT cell clonalityT cell responseT-cell receptor clonalityTCA4 proteinTCR clonalityTNFRSF5TNFRSF5 geneTeff cellTestingTumor AntigensTumor CellTumor ImmunityTumor Necrosis Factor Receptor Superfamily Member 5 GeneTumor-Associated AntigenVaccinesVeiled Cellsabsence of HPVabsence of human papillomavirusadaptive immune responsealcohol exposedalcohol exposureanti programmed cell death protein 1 inhibitoranti-PD-1 inhibitorsanti-PD1 inhibitorsanti-canceranti-cancer immunotherapyanti-tumor immune responseanti-tumor immunityanticancer immunotherapyantitumor immunitycancer antigenscancer immunitycancer immunotherapycancer microenvironmentcell motilitychemotherapycompare to controlcomparison controlcurative interventioncurative therapeuticcurative therapycurative treatmentscytotoxicdaily living functiondaily living functionalitydesigndesigningdevelopmentaldraining lymph nodeeffector T cellethanol exposedethanol exposureexodus-2exposed to alcoholexposed to ethanolexposure to alcoholexposure to ethanolflow cytophotometryfunctional abilityfunctional capacityhead and neck cancer patienthead and neck squamous carcinomahead and neck squamous cell cancerhead/neck cancerhost responsehuman modelhuman papillomavirus (-) head and neck squamous cell carcinomahuman papillomavirus - head and neck squamous cell carcinomahuman papillomavirus negativehuman papillomavirus negative head and neck cancerhuman papillomavirus negative head and neck squamous cell carcinomahuman papillomavirus- head and neck squamous cell carcinomaimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapiesimmune-based treatmentsimmuno therapyimmunoresponseimmunotherapy for cancerimmunotherapy of cancerimprovedinduction therapiesinsightirradiationlymph channellymph vessellymphatic channellymphatic vesselmalignancymalignant head and neck tumormigrationmodel of humanmortalitymouse modelmurine modelneoplasm/cancerneoplastic cellnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynon-HPV HNSCCnon-human papillomavirus head and neck squamous cell carcinomanovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachp50phase 1 trialphase 2 trialphase 3 trialphase I trialphase II protocolphase II trialphase III trialprogrammed cell death 1programmed cell death protein 1programmed death 1regional lymph noderesectionresponseresponse to therapyresponse to treatmentscRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsle2smoking exposuresocial rolespatial RNA sequencingspatial gene expression analysisspatial gene expression profilingspatial relationshipspatial resolved transcriptome sequencingspatial transcriptome analysisspatial transcriptome profilingspatial transcriptome sequencingspatial transcriptomicsspatially resolved transcriptomicsspatio transcriptomicssurgerysystemic lupus erythematosus susceptibility 2therapeutic responsetherapy responsethymus-derived chemotactic agent 4traffickingtranscriptome sequencingtranscriptomic sequencingtreatment responsetreatment responsivenesstumortumor microenvironmenttumor-specific antigen
Description preview
Project Summary
Human papilloma virus negative (HPV-) head and neck squamous cell carcinoma (HNSCC) is associated with
high mortality and current curative treatment options incur significant morbidity. Despite activity in
recurrent/metastatic settings, PD-1 inhibitors have low response rates of 14-20% in previously untreated, locally
advanced…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click